The discovery of immune checkpoints such as programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) has made a breakthrough in cancer immunology and therapy in a wide variety of cancer types, including non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.